PDF File Link Is At The End Of Article👇

----------------------------

1. Introduction

The Liver Function Test (LFT) is a group of biochemical investigations used to assess the functional status, structural integrity, and metabolic capacity of the liver. Although commonly referred to as “liver function tests,” not all parameters directly measure liver function. Some indicate hepatocellular injury, others reflect cholestasis, and some evaluate the synthetic capacity of the liver.

The liver is the largest internal organ and performs more than 500 vital physiological functions including metabolism, detoxification, protein synthesis, bile production, storage of vitamins and minerals, and regulation of glucose and lipid homeostasis. Because of this wide functional spectrum, abnormalities in LFTs can indicate a broad range of systemic and hepatic disorders.

2. Anatomy and Physiology of the Liver

Anatomy

Located in the right hypochondrium and epigastrium.
Divided into right and left lobes.
Functional unit: hepatic lobule.
Dual blood supply:
- Portal vein (75%)
- Hepatic artery (25%)

Physiological Functions

Metabolic Functions
- Carbohydrate metabolism (glycogenesis, gluconeogenesis)
- Lipid metabolism
- Protein metabolism (urea cycle)
Synthetic Functions
- Albumin
- Clotting factors (I, II, V, VII, IX, X, XI)
- Transport proteins
Excretory Functions
- Bile production
- Bilirubin conjugation
Detoxification
- Drugs
- Toxins
- Ammonia → Urea

3. Components of Liver Function Test

LFT generally includes:

Serum Bilirubin (Total, Direct, Indirect)
Alanine Aminotransferase (ALT)
Aspartate Aminotransferase (AST)
Alkaline Phosphatase (ALP)
Gamma-Glutamyl Transferase (GGT)
Serum Albumin
Total Protein
Prothrombin Time (PT/INR)
Lactate Dehydrogenase (LDH) (optional)

4. Serum Bilirubin

Physiology of Bilirubin

Produced from hemoglobin breakdown.
Unconjugated (indirect) bilirubin:
- Water-insoluble
- Bound to albumin
Conjugated (direct) bilirubin:
- Water-soluble
- Excreted in bile

Normal Values

Total bilirubin: 0.3–1.2 mg/dL
Direct bilirubin: 0–0.3 mg/dL

Clinical Significance

1. Prehepatic Jaundice

Hemolysis
Increased unconjugated bilirubin

2. Hepatic Jaundice

Hepatitis
Cirrhosis
Mixed pattern

3. Posthepatic Jaundice

Gallstones
Tumors
Increased conjugated bilirubin

5. Aminotransferases (AST & ALT)

Alanine Aminotransferase (ALT)

More specific for liver injury.
Normal: 7–56 IU/L

Aspartate Aminotransferase (AST)

Found in liver, heart, muscle.
Normal: 10–40 IU/L

AST/ALT Ratio

<1 → Viral hepatitis
2 → Alcoholic liver disease

Marked Elevation (>1000 IU/L)

Acute viral hepatitis
Drug-induced liver injury
Ischemic hepatitis

6. Alkaline Phosphatase (ALP)

Present in bile duct epithelium.
Normal: 44–147 IU/L

Elevated In:

Obstructive jaundice
Cholestasis
Bone diseases (physiological in pregnancy)

7. Gamma-Glutamyl Transferase (GGT)

Sensitive marker of cholestasis.
Elevated in:
- Alcohol abuse
- Biliary obstruction

Helps differentiate hepatic vs bone cause of raised ALP.

8. Serum Albumin

Synthesized in liver.
Normal: 3.5–5.0 g/dL

Low in:

Chronic liver disease
Malnutrition
Nephrotic syndrome

Indicates chronicity rather than acute injury.

9. Prothrombin Time (PT/INR)

Reflects synthetic function.
Prolonged in:
- Acute liver failure
- Vitamin K deficiency
- Severe chronic liver disease

Most sensitive marker of acute hepatic dysfunction.

10. Patterns of LFT Abnormalities

1. Hepatocellular Pattern

↑ AST & ALT
Mild ↑ ALP

Causes:

Viral hepatitis
Drug toxicity
Autoimmune hepatitis

2. Cholestatic Pattern

↑ ALP & GGT
Mild ↑ AST/ALT

Causes:

Gallstones
Cholangiocarcinoma
Primary biliary cholangitis

3. Mixed Pattern

Both enzymes elevated

11. LFT in Common Diseases

1. Viral Hepatitis

ALT > AST
Bilirubin ↑
PT may prolong

2. Alcoholic Liver Disease

AST > ALT (2:1)
GGT elevated

3. Cirrhosis

Mild enzyme rise
Low albumin
Prolonged PT

4. Obstructive Jaundice

ALP ↑↑
Conjugated bilirubin ↑

5. Acute Liver Failure

Massive transaminase elevation
PT markedly prolonged

12. Clinical Interpretation Approach

Stepwise approach:

Check bilirubin
Assess AST/ALT levels
Evaluate ALP & GGT
Check albumin
Review PT/INR
Correlate clinically

13. Drug-Induced Liver Injury (DILI)

Common drugs causing abnormal LFT:

Paracetamol (Acetaminophen)
Anti-tubercular drugs
Statins
Antiepileptics

Patterns:

Hepatocellular
Cholestatic
Mixed

14. LFT in Special Conditions

Pregnancy

ALP physiologically increased

Neonates

High bilirubin common

Muscle Injury

AST may rise independently

15. Limitations of LFT

Normal LFT does not exclude liver disease.
Mild elevations may be non-specific.
Requires imaging correlation (Ultrasound, CT).

16. Recent Advances

Fibroscan
Serum fibrosis markers
MELD scoring
Child-Pugh classification

1. Advanced Overview of Liver Function Tests

Liver Function Tests (LFTs) are a panel of biochemical investigations used to:

Detect hepatocellular injury
Identify cholestasis
Assess hepatic synthetic capacity
Evaluate disease severity
Monitor treatment response
Predict prognosis

It is important to emphasize that:

🔎 LFTs are not purely “function tests.”
Some parameters reflect cellular injury, others reflect biliary obstruction, and a few truly measure synthetic function.

2. Detailed Hepatic Physiology Relevant to LFT Interpretation

A. Hepatic Blood Flow & Zonal Concept

The liver acinus is divided into:

Zone	Location	Oxygen Supply	Clinical Significance
Zone 1	Periportal	Highest	First affected in viral hepatitis
Zone 2	Midzonal	Intermediate	Rarely isolated injury
Zone 3	Centrilobular	Lowest	Most vulnerable to ischemia & alcohol

Clinical Correlation:

Ischemic hepatitis → Zone 3 necrosis
Alcoholic liver disease → Centrilobular damage
Viral hepatitis → Periportal inflammation

Understanding zonal injury explains enzyme elevation patterns.

3. Detailed Biochemistry of Bilirubin

A. Bilirubin Metabolism – Stepwise

Step 1: Hemoglobin Breakdown

RBC lifespan ≈ 120 days
Heme → Biliverdin → Unconjugated bilirubin

Step 2: Transport

Unconjugated bilirubin binds albumin

Step 3: Hepatic Uptake

Taken into hepatocytes

Step 4: Conjugation

Enzyme: UDP-glucuronyl transferase
Converts to water-soluble conjugated bilirubin

Step 5: Excretion

Secreted into bile
Converted to urobilinogen in intestine

B. Hyperbilirubinemia: Deep Analysis

1. Unconjugated Hyperbilirubinemia

Causes:

Hemolysis
Ineffective erythropoiesis
Genetic defects:
- Gilbert syndrome
- Crigler-Najjar syndrome

Characteristics:

No bilirubin in urine
Normal colored stool

2. Conjugated Hyperbilirubinemia

Causes:

Obstructive jaundice
Cholangiocarcinoma
Drug-induced cholestasis

Features:

Dark urine
Pale stools
Pruritus

4. Aminotransferases – Advanced Interpretation

ALT (Alanine Aminotransferase)

Cytosolic enzyme
More specific for hepatocytes
Released during membrane damage

Elevation Magnitude:

ALT Level	Clinical Meaning
< 2× ULN	Mild fatty liver
3–20× ULN	Viral hepatitis
>1000 IU/L	Acute severe injury

AST (Aspartate Aminotransferase)

Found in liver, heart, muscle
Present in mitochondria and cytosol

AST/ALT Ratio Clinical Use:

Ratio	Interpretation
<1	Viral hepatitis
>2	Alcoholic hepatitis
>1 with cirrhosis	Advanced fibrosis

Alcohol damages mitochondria → increases AST.

5. Alkaline Phosphatase (ALP) – In Depth

Produced by:

Bile duct epithelium
Bone osteoblasts
Placenta

Isolated ALP Elevation:

Check:

GGT
5’-Nucleotidase

If GGT elevated → Hepatic source
If normal GGT → Bone source

6. Gamma-Glutamyl Transferase (GGT)

Highly sensitive but less specific
Induced by alcohol

Elevated in:

Alcoholic liver disease
Cholestasis
Pancreatic disease

Useful for confirming biliary origin of ALP.

7. Serum Albumin – Synthetic Function Marker

Half-life ≈ 20 days

Low albumin indicates:

Chronic liver disease
Advanced cirrhosis
Malnutrition

Not reliable for acute injury due to long half-life.

8. Prothrombin Time (PT/INR)

Clotting factors II, VII, IX, X are vitamin K dependent.

Important Clinical Pearls:

PT prolongation corrects with Vitamin K → Cholestasis
No correction → Severe hepatocellular failure

Most sensitive indicator of acute liver failure.

9. Patterns of Liver Injury – Advanced Classification

R Ratio Calculation

R = (ALT / ALT ULN) ÷ (ALP / ALP ULN)

R Value	Pattern
>5	Hepatocellular
<2	Cholestatic
2–5	Mixed

Used in drug-induced liver injury classification.

10. LFT in Specific Diseases – Expanded

A. Viral Hepatitis

Caused by:

Hepatitis A virus
Hepatitis B virus
Hepatitis C virus

Findings:

ALT > AST
Bilirubin elevated
PT prolonged in severe cases

B. Alcoholic Liver Disease

Pathology:

Steatosis
Steatohepatitis
Cirrhosis

LFT Pattern:

AST > ALT (2:1)
GGT elevated

C. Non-Alcoholic Fatty Liver Disease (NAFLD)

Common in:

Diabetes
Obesity
Metabolic syndrome

Mild ALT elevation.

D. Cirrhosis

Features:

Low albumin
High bilirubin
Prolonged PT
Mild enzyme elevation

E. Obstructive Jaundice

Causes:

Gallstones
Pancreatic carcinoma

Pattern:

ALP ↑↑
GGT ↑
Conjugated bilirubin ↑

11. Liver Failure

Acute Liver Failure

Criteria:

Encephalopathy
INR ≥1.5

Marked elevation of transaminases.

Common causes:

Paracetamol toxicity
Viral hepatitis

Chronic Liver Failure

Gradual synthetic decline:

Hypoalbuminemia
Prolonged PT
Hyperbilirubinemia

12. Scoring Systems

Child-Pugh Score

Parameters:

Bilirubin
Albumin
PT
Ascites
Encephalopathy

Class A → Mild
Class B → Moderate
Class C → Severe

MELD Score

Used for transplant priority.
Based on:

Bilirubin
INR
Creatinine

13. Clinical Approach to Abnormal LFT

Step 1: Confirm abnormality

Step 2: Assess pattern

Step 3: Review medications

Step 4: Order imaging (Ultrasound)

Step 5: Viral markers

Step 6: Autoimmune profile

14. Drug-Induced Liver Injury (DILI) – Deep Expansion

Types:

Intrinsic (dose-dependent)
Idiosyncratic

Common drugs:

Paracetamol
Isoniazid
Rifampicin
Statins

15. Special Populations

Pregnancy

ALP elevated (placental origin)

Neonates

Physiological jaundice

Elderly

Mild enzyme rise common

PART 1: Molecular Mechanisms of Hepatocyte Injury

Liver injury reflected in LFT abnormalities occurs through several molecular pathways:

1. Oxidative Stress

Reactive oxygen species (ROS) damage cell membranes.
Lipid peroxidation leads to hepatocyte necrosis.
Seen in alcoholic liver disease and drug toxicity.

2. Mitochondrial Dysfunction

Alcohol and toxins impair ATP production.
Leads to apoptosis and AST elevation (mitochondrial AST).

3. Immune-Mediated Injury

Cytotoxic T-cells attack infected hepatocytes.
Seen in viral hepatitis and autoimmune hepatitis.

4. Endoplasmic Reticulum Stress

Accumulation of misfolded proteins triggers inflammation.

These mechanisms explain enzyme release patterns.

PART 2: Liver Enzyme Kinetics & Half-Life

Understanding half-life helps in monitoring recovery.

Enzyme	Half-Life	Clinical Relevance
ALT	~47 hours	Slower decline after injury
AST	~17 hours	Falls faster
ALP	~7 days	Remains elevated longer
Albumin	~20 days	Marker of chronic disease

Example:

In acute hepatitis → AST rises first and falls earlier.
ALT remains elevated longer.

PART 3: Acute vs Chronic Liver Disease Differentiation

Feature	Acute	Chronic
ALT/AST	Markedly high	Mild-moderate
Albumin	Normal initially	Low
PT	May prolong suddenly	Chronically prolonged
Bilirubin	High	Variable

Key Concept:

Acute injury → enzyme elevation.
Chronic injury → synthetic failure.

PART 4: LFT in Intensive Care Settings

In ICU patients, LFT abnormalities are common due to:

Ischemic Hepatitis (“Shock Liver”)
- AST/ALT > 2000 IU/L
- Due to hypotension
Sepsis-Associated Cholestasis
- Elevated bilirubin
- Mild enzyme rise
Total Parenteral Nutrition
- Cholestatic pattern

PART 5: Liver Function in Systemic Diseases

1. Cardiac Failure

Congestive hepatopathy
Mild AST/ALT rise
Bilirubin elevation

2. Thyroid Disorders

Hyperthyroidism → mild ALT rise
Hypothyroidism → fatty liver

3. Celiac Disease

Mild transaminase elevation

LFT abnormalities may be secondary, not primary liver disease.

PART 6: Pediatric Liver Function Interpretation

Neonatal Considerations:

Physiological jaundice due to immature conjugation.
Pathological jaundice:
- Biliary atresia
- Hemolytic disease

Warning Signs:

Conjugated bilirubin in neonate → Always pathological.

PART 7: LFT in Metabolic Liver Diseases

1. Wilson Disease

Copper accumulation
Low ceruloplasmin
Mild transaminase elevation

2. Hemochromatosis

Iron overload
Mild ALT elevation
High ferritin

3. Alpha-1 Antitrypsin Deficiency

Chronic liver disease in children

These require specific confirmatory tests.

PART 8: Autoimmune Liver Diseases

Autoimmune Hepatitis

ALT markedly elevated
Positive ANA, ASMA

Primary Biliary Cholangitis

ALP elevated
Anti-mitochondrial antibodies positive

Primary Sclerosing Cholangitis

Cholestatic pattern
Associated with ulcerative colitis

PART 9: Imaging Correlation with LFT

Imaging is essential when:

ALP elevated → Look for obstruction.
Chronic enzyme elevation → Assess fibrosis.
Mass suspected → CT or MRI.

PART 10: Prognostic Value of LFT

Indicators of Poor Prognosis:

INR > 2
Bilirubin > 20 mg/dL
Rapid drop in ALT after massive rise (hepatic necrosis)
Hypoalbuminemia with ascites

Advanced Clinical Case Example

Case 1:

25-year-old male with jaundice.

LFT:

ALT: 950 IU/L
AST: 800 IU/L
ALP: Mild rise
Bilirubin: 8 mg/dL

Interpretation: → Hepatocellular pattern
Likely viral hepatitis.

Case 2:

60-year-old female with itching and pale stool.

LFT:

ALP: 600 IU/L
GGT: High
Conjugated bilirubin elevated

Interpretation: → Obstructive jaundice.

Ultra-Advanced Clinical Pearls

✔ AST > ALT → Think alcohol
✔ ALT > AST → Think viral
✔ ALP + GGT ↑ → Cholestasis
✔ PT prolonged → Severe dysfunction
✔ Low albumin → Chronic disease

PART 11: Liver Synthetic Function – Deep Biochemical Analysis

True “function” of the liver is best reflected by:

Albumin synthesis
Clotting factor production
Cholesterol synthesis
Glucose homeostasis

A. Albumin Synthesis Regulation

Produced exclusively by hepatocytes.
Regulated by:
- Nutritional status
- Cytokines (IL-6 decreases production in inflammation)

Low albumin may reflect:

Chronic liver disease
Severe inflammation (negative acute phase reactant)
Protein loss

B. Coagulation Factors & PT

Clotting factors produced in liver:

Fibrinogen (I)
Prothrombin (II)
V, VII, IX, X, XI

Factor VII has shortest half-life → PT rises early in acute failure.

Thus:

PT/INR is the most sensitive indicator of acute hepatic failure.

PART 12: Acute Liver Failure (ALF) – Detailed Mechanisms

Definition:

Rapid liver dysfunction
INR ≥1.5
Encephalopathy
No pre-existing cirrhosis

Common Causes:

Paracetamol toxicity
Viral hepatitis
Autoimmune hepatitis
Mushroom poisoning

Pathophysiology

Massive hepatocyte necrosis
Cytokine storm
Cerebral edema
Multi-organ failure

LFT Findings:

AST/ALT often >3000 IU/L
PT markedly prolonged
Bilirubin rising

PART 13: Chronic Liver Disease & Fibrosis Progression

Fibrosis Mechanism

Chronic inflammation
Activation of hepatic stellate cells
Collagen deposition
Architectural distortion → Cirrhosis

LFT Pattern in Fibrosis

Mild ALT elevation
Normal or slightly high ALP
Low albumin (late)
High bilirubin (late)

Important: LFT may be nearly normal in compensated cirrhosis.

PART 14: Portal Hypertension & LFT

Portal hypertension results from:

Increased intrahepatic resistance
Fibrotic distortion

Consequences:

Ascites
Varices
Splenomegaly

LFT findings:

Thrombocytopenia (due to splenic sequestration)
Mild bilirubin rise

PART 15: Cholestasis – Cellular & Molecular View

Types:

1. Intrahepatic

Drug-induced
Viral hepatitis
Primary biliary cholangitis

2. Extrahepatic

Gallstones
Pancreatic tumor

Biochemical Pattern

ALP ↑↑
GGT ↑↑
Conjugated bilirubin ↑

Mechanism

Bile salt accumulation:

Damages membranes
Causes pruritus
Leads to fat malabsorption

PART 16: Liver Transplantation & LFT

Indications:

End-stage cirrhosis
Acute liver failure
Hepatocellular carcinoma (selected cases)

Post-Transplant LFT Monitoring

Early:

AST/ALT elevated (ischemia-reperfusion injury)

Rejection:

Rising bilirubin
Elevated ALP

Biliary complication:

ALP & GGT elevation

PART 17: Hepatocellular Carcinoma (HCC) & LFT

HCC often develops on cirrhotic background.

LFT findings:

Mild transaminase elevation
Elevated bilirubin (late)
Alpha-fetoprotein elevated

Screening recommended in cirrhosis.

PART 18: Drug-Induced Liver Injury – Advanced Classification

Types:

1. Hepatocellular

ALT predominant

2. Cholestatic

ALP predominant

3. Mixed

Mechanisms:

Direct toxicity
Immune-mediated
Idiosyncratic reactions

Examples:

Paracetamol → Massive necrosis
Isoniazid → Hepatocellular
Amoxicillin-clavulanate → Cholestatic

PART 19: Emerging Biomarkers Beyond Traditional LFT

Modern hepatology uses:

FibroScan (Transient elastography)
Enhanced Liver Fibrosis (ELF) score
Cytokeratin-18 fragments
MicroRNA markers

These help detect fibrosis earlier than routine LFT.

PART 20: Algorithmic Clinical Interpretation

Stepwise Algorithm

Is bilirubin elevated?
- Yes → Conjugated or unconjugated?
Are AST/ALT elevated?
- 1000 → Acute injury
- Mild → Chronic/metabolic
Is ALP elevated?
- Yes → Check GGT
Is albumin low?
- Yes → Chronic disease
Is PT prolonged?

Yes → Severe dysfunction

PART 21: Immunology of Liver Injury

The liver is an immunologically unique organ.

Why?

Receives blood from gut (rich in antigens).
Contains specialized immune cells:
- Kupffer cells (resident macrophages)
- Natural killer (NK) cells
- T lymphocytes
- Dendritic cells

A. Immune-Mediated Hepatocyte Damage

Occurs in:

Autoimmune hepatitis
Primary biliary cholangitis
Primary sclerosing cholangitis

Mechanism:

Loss of immune tolerance
Autoantibody formation
Cytotoxic T-cell activation
Progressive inflammation → fibrosis

LFT Pattern:

Marked ALT elevation (autoimmune hepatitis)
ALP predominant (cholestatic autoimmune diseases)

PART 22: Cytokines & Inflammatory Mediators in LFT Elevation

Key cytokines:

TNF-α
IL-1
IL-6
TGF-β

Effects:

Suppress albumin synthesis
Promote fibrosis
Induce apoptosis

IL-6 explains why albumin falls during systemic inflammation even without severe liver failure.

PART 23: Metabolic Liver Disease & LFT

A. Non-Alcoholic Fatty Liver Disease (NAFLD)

Associated with:

Obesity
Diabetes
Dyslipidemia

Progression: Steatosis → NASH → Fibrosis → Cirrhosis

LFT:

Mild ALT elevation
ALT > AST early
AST > ALT in advanced fibrosis

B. Wilson Disease

Copper accumulation
Low ceruloplasmin
AST/ALT elevated
Hemolysis may increase bilirubin

C. Hemochromatosis

Iron overload
Ferritin elevated
Mild ALT rise
Bronze skin pigmentation

PART 24: Ischemic Hepatitis (“Shock Liver”)

Occurs in:

Severe hypotension
Cardiac arrest
Septic shock

Mechanism:

Zone 3 (centrilobular) necrosis

LFT:

AST/ALT > 5000 IU/L
Rapid fall within 72 hours if perfusion restored

Key clue: Massive enzyme elevation with history of shock.

PART 25: Pregnancy & Liver Function Tests

Physiological changes:

ALP increases (placental source)
Albumin slightly decreases (hemodilution)

Pathological conditions:

1. HELLP Syndrome

Hemolysis
Elevated liver enzymes
Low platelets

2. Acute Fatty Liver of Pregnancy

Severe liver dysfunction
Hypoglycemia
Elevated bilirubin

PART 26: Pediatric Hepatology & LFT Interpretation

Neonatal conjugated hyperbilirubinemia is ALWAYS pathological.

Causes:

Biliary atresia
Metabolic disorders
Infections

Early diagnosis critical to prevent irreversible cirrhosis.

PART 27: Hepatic Encephalopathy & Biochemical Correlation

Mechanism:

Ammonia accumulation
Failure of urea cycle

LFT may show:

Mild enzyme rise
Severe PT prolongation
High bilirubin

Severity graded I–IV.

PART 28: Liver & Endocrine System Interactions

Thyroid Disorders

Hyperthyroidism → mild ALT elevation
Hypothyroidism → fatty liver

Diabetes Mellitus

Strongly associated with NAFLD
Insulin resistance drives steatosis

Cushing Syndrome

Steroid-induced fatty liver

PART 29: Liver Biopsy Correlation with LFT

Indications:

Unexplained persistent LFT elevation
Suspected autoimmune hepatitis
Staging fibrosis

Important: LFT does NOT correlate directly with degree of fibrosis.

A patient may have:

Mild ALT
Advanced cirrhosis on biopsy

PART 30: Future of Liver Diagnostics

Emerging tools:

Artificial Intelligence in LFT interpretation
Genetic risk profiling
Serum microRNA panels
Proteomic markers
Non-invasive fibrosis scoring algorithms

Goal: Detect disease before irreversible fibrosis develops.

Integrated Clinical Master Framework

When interpreting LFT always think:

1️⃣ Injury?

(AST/ALT)

2️⃣ Cholestasis?

(ALP/GGT)

3️⃣ Function?

(Albumin/PT)

4️⃣ Chronicity?

(Albumin trend)

5️⃣ Severity?

(INR + Bilirubin)

PART 31: Hepatorenal Syndrome (HRS) & LFT Correlation

Definition:

Functional renal failure occurring in advanced liver disease.

Associated with:

Decompensated cirrhosis
Severe portal hypertension
Refractory ascites

Pathophysiology:

Splanchnic vasodilation
Reduced effective arterial volume
Renal vasoconstriction
Progressive renal failure

LFT Pattern:

Elevated bilirubin
Low albumin
Prolonged PT
Mild AST/ALT elevation

Severity of bilirubin and INR predicts mortality.

PART 32: Hepatopulmonary Syndrome (HPS)

Occurs in advanced cirrhosis.

Mechanism:

Pulmonary vascular dilation
Impaired oxygen exchange

Symptoms:

Dyspnea
Platypnea (worse standing)

LFT:

Reflects severity of underlying cirrhosis
Hypoalbuminemia
Elevated bilirubin

PART 33: Portal Vein Thrombosis (PVT)

Causes:

Cirrhosis
Malignancy
Hypercoagulable states

LFT:

May be near normal early
Mild transaminase rise
Worsening bilirubin if severe

Important: Normal LFT does NOT exclude vascular pathology.

PART 34: Budd–Chiari Syndrome

Definition:

Hepatic vein thrombosis causing hepatic congestion.

Mechanism:

Outflow obstruction
Liver congestion
Ischemia

LFT:

AST/ALT moderately elevated
Bilirubin elevated
ALP mildly raised

Clinical triad:

Abdominal pain
Ascites
Hepatomegaly

PART 35: Sepsis-Associated Liver Dysfunction

In ICU settings:

Mechanism:

Cytokine storm
Microcirculatory failure
Endotoxin exposure

Pattern:

Elevated bilirubin
Mild AST/ALT elevation
ALP moderately raised

Known as “Sepsis-Induced Cholestasis.”

PART 36: Alcoholic Liver Disease – Advanced Biochemistry

Stages:

Fatty liver
Alcoholic hepatitis
Cirrhosis

Key LFT features:

AST > ALT (2:1 ratio)
GGT elevated
Bilirubin high in severe hepatitis

Why AST predominates?

Alcohol damages mitochondria
AST has mitochondrial fraction

PART 37: Autoimmune Hepatitis – Deep Diagnostic Interpretation

Associated antibodies:

ANA
Anti-smooth muscle antibody (ASMA)
Anti-LKM1

LFT pattern:

ALT markedly elevated
Hypergammaglobulinemia
Bilirubin variable

Untreated → Rapid progression to cirrhosis.

PART 38: Primary Biliary Cholangitis (PBC)

Autoimmune destruction of small intrahepatic bile ducts.

LFT:

ALP markedly elevated
GGT elevated
Mild ALT rise

Symptoms:

Pruritus
Fatigue
Xanthelasma

PART 39: Primary Sclerosing Cholangitis (PSC)

Often associated with ulcerative colitis.

Pathology:

Progressive fibrosis of bile ducts

LFT:

Cholestatic pattern
ALP high
Bilirubin elevated (late)

Risk:

Cholangiocarcinoma

PART 40: Hepatocellular Carcinoma (HCC) – Advanced Monitoring

Develops mostly in cirrhotic liver.

LFT findings:

Mild enzyme elevation
Rising bilirubin
Worsening albumin in advanced disease

Screening:

Ultrasound every 6 months in cirrhosis
AFP monitoring

Integrated Expert-Level Interpretation Framework

When you see abnormal LFT, ask:

1️⃣ Is it hepatocellular?

(AST/ALT predominant)

2️⃣ Is it cholestatic?

(ALP/GGT predominant)

3️⃣ Is there synthetic failure?

(Albumin ↓, PT ↑)

4️⃣ Is there vascular pathology?

(Consider Budd–Chiari, PVT)

5️⃣ Is it systemic?

(Sepsis, heart failure, endocrine disease)

PART 41: Transplant Immunology & LFT Monitoring

After liver transplantation, LFT trends are critical.

A. Immediate Post-Transplant Phase

Expected:

AST/ALT elevation (ischemia-reperfusion injury)
Mild bilirubin rise

Concerning signs:

Rapid bilirubin increase
Persistent ALT > 2000 IU/L
INR worsening

B. Acute Cellular Rejection

Mechanism:

T-cell mediated attack on graft

LFT Pattern:

Rising ALP
Elevated bilirubin
Moderate AST/ALT increase

Confirmed by biopsy.

C. Chronic Rejection

Progressive cholestasis
Increasing ALP & GGT
Gradual graft failure

PART 42: Molecular Genetics of Liver Diseases

A. Genetic Cholestatic Disorders

Examples:

Progressive familial intrahepatic cholestasis
Alagille syndrome

LFT:

Markedly elevated ALP
Conjugated hyperbilirubinemia

B. Genetic Metabolic Disorders

1. Wilson Disease

(ATP7B mutation)

2. Hemochromatosis

(HFE gene mutation)

Genetic testing complements LFT abnormalities.

PART 43: Advanced Pharmacotoxicology of the Liver

The liver metabolizes drugs via:

Phase I (Cytochrome P450)
Phase II (Conjugation)

A. Intrinsic Toxicity

Dose-dependent:

Paracetamol overdose
Direct mitochondrial damage

AST/ALT > 3000 IU/L

B. Idiosyncratic Toxicity

Unpredictable:

Anti-tubercular drugs
Antibiotics
Antiepileptics

May show hepatocellular or cholestatic pattern.

PART 44: Cytochrome P450 & LFT

CYP450 enzymes:

CYP3A4
CYP2E1 (alcohol metabolism)
CYP2D6

Drug interactions may:

Increase toxicity
Elevate liver enzymes

Alcohol induces CYP2E1 → increases paracetamol toxicity.

PART 45: Advanced ICU Hepatology

In critically ill patients, LFT abnormalities are common.

A. Hypoxic Hepatitis

AST/ALT > 5000 IU/L
Rapid normalization if circulation restored

B. Total Parenteral Nutrition (TPN)

Cholestatic pattern
Elevated ALP & bilirubin

C. Drug-Induced ICU Cholestasis

Sedatives
Antibiotics

PART 46: Hepatic Microcirculation & LFT

Liver sinusoids:

Low-pressure vascular channels
Lined by endothelial cells

In cirrhosis:

Sinusoidal capillarization
Increased resistance
Portal hypertension

LFT may remain near normal despite severe microvascular distortion.

PART 47: Fibrosis Biomarkers Beyond LFT

Traditional LFT cannot stage fibrosis accurately.

Modern tools:

APRI score
FIB-4 score
ELF score
Transient elastography

APRI uses: (AST / Platelet count)

Non-invasive markers reduce need for biopsy.

PART 48: Hepatic Stem Cells & Regeneration

The liver has remarkable regenerative capacity.

Mechanisms:

Hepatocyte replication
Activation of oval cells

After injury:

ALT rises
Regeneration begins within 24–48 hours

Failure of regeneration → acute liver failure.

PART 49: Systemic Inflammatory Response & Liver

In systemic inflammation:

Albumin decreases (negative acute phase protein)
CRP increases
Bilirubin may rise

Thus low albumin may reflect systemic illness, not just liver disease.

PART 50: Ultimate Expert Clinical Algorithm

When faced with abnormal LFT:

Step 1

Confirm repeat test.

Step 2

Classify pattern:

Hepatocellular
Cholestatic
Mixed

Step 3

Assess severity:

INR
Bilirubin
Albumin

Step 4

Evaluate risk factors:

Alcohol
Drugs
Viral exposure
Metabolic syndrome

Step 5

Order targeted investigations:

Viral markers
Autoimmune profile
Iron studies
Copper studies
Imaging

PART 51: Acute-on-Chronic Liver Failure (ACLF)

Definition:

Acute deterioration of liver function in a patient with pre-existing chronic liver disease.

Common triggers:

Infection
Alcohol binge
Drug toxicity
GI bleeding

LFT Pattern:

Sudden rise in bilirubin
Sharp increase in INR
Moderate AST/ALT rise

Prognosis depends on:

Number of organ failures
Degree of coagulopathy

ACLF carries very high short-term mortality.

PART 52: Coagulopathy in Liver Disease – Deep Analysis

Liver synthesizes both:

Pro-coagulant factors
Anti-coagulant factors (Protein C, S, Antithrombin)

Thus liver disease creates a rebalanced but unstable hemostatic system.

LFT Interpretation:

Prolonged PT does not always mean bleeding risk.
Thrombosis (e.g., portal vein thrombosis) can still occur.

Advanced tests:

Thromboelastography (TEG)

PART 53: Hepatic Glycogen Storage & Metabolic Crisis

In acute liver failure:

Gluconeogenesis impaired
Glycogen stores depleted

Results:

Hypoglycemia
Lactic acidosis

Thus in severe liver dysfunction: Low glucose is a dangerous sign.

PART 54: Hyperbilirubinemia – Advanced Clinical Patterns

A. Isolated Indirect Hyperbilirubinemia

Hemolysis
Gilbert syndrome

B. Isolated Direct Hyperbilirubinemia

Obstruction
Cholestasis

C. Mixed Pattern

Viral hepatitis
Drug injury

Important: Dark urine → conjugated bilirubin present.

PART 55: Rare Genetic Hyperbilirubinemias

Examples:

Gilbert syndrome
Crigler-Najjar syndrome
Dubin-Johnson syndrome

LFT:

Mostly normal except bilirubin abnormality.

Clinical pearl: Isolated bilirubin abnormality with normal enzymes often benign.

PART 56: Hepatic Vascular Disorders & LFT

A. Congestive Hepatopathy

Seen in:

Right heart failure

LFT:

Mild AST/ALT rise
Bilirubin mildly elevated

B. Sinusoidal Obstruction Syndrome

Occurs after:

Chemotherapy
Bone marrow transplant

Pattern:

Bilirubin elevation
Moderate enzyme rise

PART 57: Hepatic Endocrine Functions

The liver metabolizes:

Estrogen
Cortisol
Insulin
Thyroid hormones

In cirrhosis:

Estrogen excess → spider angiomas
Hypogonadism
Gynecomastia

LFT abnormalities correlate with hormonal imbalance severity.

PART 58: Nutrition & Liver Function

Malnutrition affects:

Albumin synthesis
Clotting factor production

In advanced liver disease:

Protein-calorie malnutrition common
Sarcopenia worsens prognosis

Albumin low may reflect both liver failure and poor nutrition.

PART 59: Liver and Inflammation – Acute Phase Reactants

Positive acute phase proteins:

CRP
Fibrinogen

Negative acute phase proteins:

Albumin
Transferrin

During systemic inflammation: Albumin decreases even if liver function is adequate.

Thus interpretation must consider inflammatory state.

PART 60: Comprehensive Grand Integration Model

When evaluating abnormal LFT, think in 6 domains:

1️⃣ Structural Damage

(AST/ALT)

2️⃣ Biliary Obstruction

(ALP/GGT)

3️⃣ Synthetic Failure

(Albumin/PT)

4️⃣ Vascular Pathology

(Budd–Chiari, PVT)

5️⃣ Systemic Illness

(Sepsis, heart failure, endocrine)

6️⃣ Genetic/Metabolic Disorders

🔬 Ultimate Clinical Philosophy

LFT is not just a test panel.

It is:

A reflection of hepatocyte integrity
A window into biliary flow
A marker of synthetic reserve
A prognostic indicator
A guide to transplant timing
A systemic disease indicator

PART 61: Gut–Liver Axis & LFT Abnormalities

The liver receives ~75% of blood from the portal vein, directly from the intestine.

Mechanism:

Increased gut permeability
Bacterial endotoxin translocation
Kupffer cell activation
Cytokine release

Seen in:

Cirrhosis
Alcoholic liver disease
NAFLD

LFT Pattern:

Mild transaminase rise
Progressive bilirubin elevation in advanced stages

Disruption of gut microbiota significantly influences liver inflammation.

PART 62: Microbiome & Cholestasis

Altered intestinal flora affects:

Bile acid metabolism
Enterohepatic circulation
FXR receptor signaling

Cholestasis leads to:

Bile acid accumulation
Hepatocyte membrane damage
Elevated ALP & GGT

Emerging research shows microbiome-targeted therapies may normalize LFT trends.

PART 63: Cardio-Hepatic Interactions

A. Congestive Hepatopathy

Right-sided heart failure causes:

Hepatic venous congestion
Centrilobular hypoxia

LFT:

Mild AST/ALT elevation
Bilirubin mildly raised

B. Ischemic Hepatitis

Due to:

Severe hypotension
Cardiogenic shock

AST/ALT may exceed 5000 IU/L.

PART 64: Hepato-Endocrine-Metabolic Axis

A. Insulin Resistance

Drives:

Hepatic steatosis
Inflammation
Fibrosis

LFT:

ALT mildly elevated

B. Thyroid Disorders

Hyperthyroidism:

Mild ALT rise

Hypothyroidism:

Associated fatty liver

Endocrine disorders can subtly alter LFT.

PART 65: Hepatic Oncology – Beyond HCC

A. Cholangiocarcinoma

LFT:

ALP markedly elevated
Conjugated bilirubin high

B. Liver Metastases

Often from:

Colon cancer
Pancreatic cancer

LFT:

ALP elevated
Mild AST/ALT rise

Tumor infiltration may produce cholestatic pattern.

PART 66: Advanced Scoring Systems in Hepatology

A. MELD-Na Score

Incorporates:

Bilirubin
INR
Creatinine
Sodium

Used for transplant allocation.

B. Child-Pugh Score

Parameters:

Albumin
Bilirubin
INR
Ascites
Encephalopathy

Class C → worst prognosis.

C. CLIF-C ACLF Score

Used in acute-on-chronic liver failure.

PART 67: Hepatic Mitochondrial Dysfunction

Mitochondria regulate:

ATP production
Apoptosis
Reactive oxygen species

Alcohol and toxins:

Impair mitochondrial function
Increase AST (mitochondrial isoenzyme)

Mitochondrial injury is central in:

Alcoholic hepatitis
Drug toxicity
Ischemic injury

PART 68: Epigenetics & Liver Disease

Epigenetic changes:

DNA methylation
Histone modification
microRNA regulation

These alter:

Inflammatory gene expression
Fibrosis progression

Emerging biomarkers may predict LFT abnormalities before enzyme elevation.

PART 69: Artificial Intelligence in LFT Interpretation

AI models analyze:

Enzyme patterns
Demographics
Imaging data
Clinical history

Machine learning can:

Predict fibrosis stage
Predict transplant need
Differentiate DILI vs viral hepatitis

Future hepatology will integrate AI-guided LFT interpretation.

PART 70: Master-Level Integrated Diagnostic Grid

When interpreting LFT, analyze across 10 dimensions:

Magnitude of AST/ALT
AST/ALT ratio
ALP & GGT pattern
Bilirubin fraction
Albumin trend
INR progression
Clinical timeline
Risk factors
Imaging findings
Systemic involvement

PART 71: Infiltrative Liver Diseases & LFT

Infiltrative diseases replace normal hepatocytes with abnormal tissue.

Examples:

Amyloidosis
Lymphoma
Sarcoidosis

LFT Pattern:

ALP disproportionately elevated
Mild AST/ALT elevation
Bilirubin may be normal early

Clinical Pearl: Marked ALP with minimal symptoms → think infiltrative process.

PART 72: Granulomatous Liver Disease

Causes:

Tuberculosis
Sarcoidosis
Fungal infections

Mechanism: Granuloma formation in portal tracts.

LFT:

ALP elevated
Mild transaminase rise

Biopsy confirms diagnosis.

PART 73: Paraneoplastic Liver Dysfunction

Stauffer Syndrome

Associated with renal cell carcinoma.

Features:

Elevated ALP
Hepatomegaly
No liver metastasis

Mechanism: Cytokine-mediated dysfunction.

LFT normalizes after tumor removal.

PART 74: Cholangiopathies Beyond PSC & PBC

Includes:

IgG4-related cholangitis
Secondary sclerosing cholangitis
AIDS cholangiopathy

LFT:

ALP markedly elevated
Conjugated bilirubin elevated

Important: Differentiate from malignancy.

PART 75: Liver in Hematological Disorders

A. Hemolysis

Indirect bilirubin elevated
AST mildly elevated

B. Leukemia/Lymphoma Infiltration

ALP elevated
Mild transaminase rise

C. Sickle Cell Crisis

Ischemic hepatic injury
Bilirubin markedly elevated

PART 76: Liver & Autoimmune Systemic Diseases

Seen in:

Systemic lupus erythematosus
Rheumatoid arthritis
Sjögren syndrome

LFT:

Mild ALT rise
Drug-induced pattern common

Always evaluate medications.

PART 77: Hepatic Complications of Obesity & Metabolic Syndrome

Progression: Steatosis → Steatohepatitis → Fibrosis → Cirrhosis

LFT:

ALT mild elevation
ALT > AST early
AST > ALT in advanced disease

Metabolic syndrome is now leading cause of chronic LFT abnormalities worldwide.

PART 78: Advanced Hepatic Vascular Physiology

Portal pressure normal: 5–10 mmHg

Portal hypertension:

12 mmHg

Consequences:

Varices
Ascites
Hypersplenism

LFT may remain mildly abnormal despite severe portal hypertension.

PART 79: Hepatic Protein Synthesis & Advanced Biomarkers

Besides albumin, liver synthesizes:

Transferrin
Ceruloplasmin
Complement proteins
Clotting factors

Decline in synthetic proteins signals decompensation.

Advanced markers:

Factor V level (sensitive in acute failure)
Prealbumin (shorter half-life than albumin)

PART 80: Ultra-Advanced Prognostic Indicators

Poor prognosis indicators include:

INR > 2.5
Bilirubin > 25 mg/dL
Rapid fall of AST after massive spike
Rising creatinine (hepatorenal syndrome)
Severe lactic acidosis

Dynamic trends more important than single value.

PART 81: Multi-Organ Failure & Liver Dysfunction

In critical illness, the liver is both a victim and a driver of multi-organ failure.

Mechanisms:

Hypoperfusion
Cytokine storm
Mitochondrial dysfunction
Endotoxin-mediated injury

LFT Pattern:

Moderate AST/ALT elevation
Rising bilirubin
Worsening INR

When bilirubin rises progressively in ICU → poor prognostic sign.

PART 82: Hepatic Contribution to Systemic Inflammation

The liver produces:

Acute phase proteins
Complement proteins
Coagulation mediators

In liver failure:

Immune dysfunction occurs
Increased susceptibility to infection

This condition is called Cirrhosis-Associated Immune Dysfunction (CAID).

LFT may not appear severely abnormal despite immune collapse.

PART 83: Advanced Fibrogenesis Signaling Pathways

Fibrosis is regulated by:

TGF-β pathway
PDGF pathway
NF-κB signaling

Activation leads to:

Hepatic stellate cell transformation
Collagen deposition
Architectural distortion

LFT:

Mild enzyme rise
Late synthetic failure

Fibrosis progression does not correlate linearly with ALT level.

PART 84: Liver–Brain Axis in Hepatic Encephalopathy

Mechanism:

Ammonia crosses blood-brain barrier
Astrocyte swelling
Cerebral edema

LFT:

Severe coagulopathy
Hyperbilirubinemia
Often mild AST/ALT rise

Severity of encephalopathy does not always correlate with enzyme elevation.

PART 85: Rare Toxic Liver Injuries

Examples:

Mushroom poisoning (Amanita phalloides)
Industrial toxins
Herbal medications

Pattern:

Massive AST/ALT elevation
Severe INR prolongation
Rapid clinical deterioration

Toxin-induced injury often follows biphasic course: Initial mild symptoms → sudden liver failure.

PART 86: Advanced Alcohol Metabolism & LFT

Alcohol metabolism pathways:

Alcohol dehydrogenase
CYP2E1 system
Catalase pathway

Effects:

NADH accumulation
Fat accumulation
Mitochondrial injury

LFT:

AST > ALT
GGT elevated
Bilirubin elevated in severe disease

PART 87: Hepatic Iron & Copper Toxicity

A. Iron Overload

Mechanism:

Free radical formation
Lipid peroxidation

LFT:

Mild ALT elevation
Progressive fibrosis

B. Copper Toxicity

Mechanism:

Mitochondrial injury
Hemolysis

LFT:

AST/ALT elevated
Indirect bilirubin from hemolysis

PART 88: End-Stage Cirrhosis – Biochemical Collapse

In decompensated cirrhosis:

Albumin very low
INR markedly prolonged
Bilirubin elevated
AST/ALT may be near normal

Important concept: Low enzymes do not mean recovery — may reflect loss of functioning hepatocytes.

PART 89: Hepatic Regeneration Failure

Normally:

Liver regenerates after injury.

In severe injury:

Stem cell response inadequate
Massive necrosis
Progressive failure

Indicators:

Persistent high INR
Rising bilirubin
Falling transaminases after initial spike

Suggests poor prognosis.

PART 90: Dynamic Trend Analysis of LFT

Single value interpretation is insufficient.

Always analyze:

Rate of rise
Rate of fall
Serial measurements
Clinical context

Example: Rapid AST decline after extreme elevation → may indicate massive necrosis.

Trend > absolute value.

PART 91: Precision Medicine & Liver Function Testing

Modern hepatology is moving toward individualized interpretation.

Instead of using only fixed “normal ranges,” precision medicine considers:

Age

Sex
Ethnicity
Genetic polymorphisms
Metabolic profile

Example: A mildly elevated ALT in an obese diabetic patient may represent early metabolic dysfunction even if within traditional reference limits.

Future LFT interpretation will be patient-specific, not population-based.

PART 92: Systems Biology Approach to Liver Disease

The liver operates as a systems network:

Metabolic regulation
Immune modulation
Endocrine integration
Detoxification pathways

LFT abnormalities reflect network disruption rather than isolated cell injury.

Systems biology integrates:

Genomics
Proteomics
Metabolomics
Microbiome data

This approach predicts disease progression before overt enzyme elevation.

PART 93: Liver–Kidney–Brain Axis

In advanced liver disease:

Liver failure → Ammonia ↑
Brain dysfunction → Encephalopathy
Kidney vasoconstriction → Hepatorenal syndrome

Biochemical cascade:

Bilirubin rising
INR prolonged
Creatinine increasing

Combined deterioration predicts mortality.

PART 94: Advanced Transplant Threshold Indicators

Transplant referral is urgent when:

MELD score > 15
INR persistently > 1.8
Bilirubin progressively rising
Recurrent ascites
Recurrent encephalopathy

Dynamic worsening more important than static number.

PART 95: Cellular Death Pathways in Liver Injury

Hepatocyte death occurs via:

Necrosis
Apoptosis
Necroptosis
Pyroptosis

Each pathway releases intracellular enzymes.

Massive necrosis → very high AST/ALT
Apoptosis → moderate elevation

Understanding cell death type helps predict reversibility.

PART 96: Artificial Intelligence Risk Stratification Models

Modern AI can:

Predict fibrosis stage using routine LFT
Predict cirrhosis risk
Predict mortality
Differentiate viral vs alcoholic hepatitis

AI models combine:

LFT values
Platelet count
Demographics
Imaging findings

Future hepatology will rely on predictive algorithms integrated into laboratory systems.

PART 97: Global Epidemiology & LFT Patterns

Leading global causes of abnormal LFT:

Metabolic-associated fatty liver disease
Alcoholic liver disease
Viral hepatitis
Drug-induced liver injury

Patterns vary by region.

In South Asia:

Viral hepatitis remains common.
Metabolic syndrome increasing rapidly.

Understanding epidemiology improves diagnostic probability.

PART 98: Ethical & Clinical Decision-Making in Severe Liver Disease

When LFT shows severe failure:

INR > 3
Bilirubin > 30 mg/dL
Multi-organ involvement

Decisions include:

ICU escalation
Transplant candidacy
Palliative care

LFT trends guide ethical clinical judgment.

PART 99: Ultimate Clinical Synthesis Model

At master level, interpret LFT through five master questions:

1️⃣ Is there injury?

(AST/ALT)

2️⃣ Is there obstruction?

(ALP/GGT)

3️⃣ Is function preserved?

(Albumin/PT)

4️⃣ Is there progression?

(Trend over time)

5️⃣ Is transplant needed?

(MELD/clinical decompensation)

This framework prevents misinterpretation.

PART 100: The Complete Philosophy of Liver Function Testing

Liver Function Tests are:

A biochemical mirror of hepatocyte integrity
A dynamic indicator of bile flow
A measure of synthetic reserve
A prognostic instrument
A transplant decision tool
A systemic disease signal

They must never be interpreted in isolation.

True expertise requires:

✔ Pathophysiological understanding
✔ Trend analysis
✔ Pattern recognition
✔ Clinical correlation
✔ Knowledge of systemic interactions
✔ Awareness of molecular mechanisms
✔ Awareness of emerging technologies

🏆 FINAL MASTER CONCLUSION

You now have a 100-part ultra-comprehensive academic expansion of Liver Function Tests covering:

Basic physiology
Advanced biochemistry
Disease patterns
Vascular disorders
Autoimmune conditions
Oncology
Transplant medicine
ICU hepatology
Molecular signaling
Precision medicine
AI integration
Prognostic modeling

This is equivalent to a postgraduate hepatology reference framework.

LIVER FUNCTION TEST (LFT): A COMPLETE COMPREHENSIVE REVIEW

PDF File Link Is At The End Of Article👇

----------------------------

1. Introduction

2. Anatomy and Physiology of the Liver

Anatomy

Physiological Functions

3. Components of Liver Function Test

4. Serum Bilirubin

Physiology of Bilirubin

Normal Values

Clinical Significance

1. Prehepatic Jaundice

2. Hepatic Jaundice

3. Posthepatic Jaundice

5. Aminotransferases (AST & ALT)

Alanine Aminotransferase (ALT)

Aspartate Aminotransferase (AST)

AST/ALT Ratio

Marked Elevation (>1000 IU/L)

6. Alkaline Phosphatase (ALP)

Elevated In:

7. Gamma-Glutamyl Transferase (GGT)

8. Serum Albumin

Low in:

9. Prothrombin Time (PT/INR)

10. Patterns of LFT Abnormalities

1. Hepatocellular Pattern

2. Cholestatic Pattern

3. Mixed Pattern

11. LFT in Common Diseases

1. Viral Hepatitis

2. Alcoholic Liver Disease

3. Cirrhosis

4. Obstructive Jaundice

5. Acute Liver Failure

12. Clinical Interpretation Approach

13. Drug-Induced Liver Injury (DILI)

14. LFT in Special Conditions

Pregnancy

Neonates

Muscle Injury

15. Limitations of LFT

16. Recent Advances

1. Advanced Overview of Liver Function Tests

2. Detailed Hepatic Physiology Relevant to LFT Interpretation

A. Hepatic Blood Flow & Zonal Concept

Clinical Correlation:

3. Detailed Biochemistry of Bilirubin

A. Bilirubin Metabolism – Stepwise

Step 1: Hemoglobin Breakdown

Step 2: Transport

Step 3: Hepatic Uptake

Step 4: Conjugation

Step 5: Excretion

B. Hyperbilirubinemia: Deep Analysis

1. Unconjugated Hyperbilirubinemia

2. Conjugated Hyperbilirubinemia

4. Aminotransferases – Advanced Interpretation

ALT (Alanine Aminotransferase)

Elevation Magnitude:

AST (Aspartate Aminotransferase)

AST/ALT Ratio Clinical Use:

5. Alkaline Phosphatase (ALP) – In Depth

Isolated ALP Elevation:

6. Gamma-Glutamyl Transferase (GGT)

7. Serum Albumin – Synthetic Function Marker

8. Prothrombin Time (PT/INR)

Important Clinical Pearls:

9. Patterns of Liver Injury – Advanced Classification

R Ratio Calculation

10. LFT in Specific Diseases – Expanded

A. Viral Hepatitis

B. Alcoholic Liver Disease

C. Non-Alcoholic Fatty Liver Disease (NAFLD)

D. Cirrhosis

E. Obstructive Jaundice

11. Liver Failure

Acute Liver Failure

Chronic Liver Failure